SNY Financials: Sanofi AI Analysis



Financials

SNY Financial

Sanofi

$43.77

0.94%

$0.41

At close: May 06, 16:00:00 GMT-4

$43.29

-1.09%

$-0.48

Pre-market: May 07, 08:42:11 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$43.36

Open

$43.62

Day's Range

$43.29 - $43.96

52 week range

$43.1 - $53.36

Volume

1.7M

Avg.Volume

3.7M

Dividend yield

EPS (TTM)

2.32

Market Cap

$103.7B

What is Sanofi?

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	57,960	11,244	25,375	--	21,341	--
Revenue Growth (YoY)	--	--	16%	--	7%	--
Cost of Revenue	16,187	3,138	7,168	--	5,881	--
Gross Profit	41,773	8,106	18,207	--	15,460	--
Selling, General & Admin	11,870	2,327	5,037	--	4,506	--
Research & Development	9,589	1,747	4,125	--	3,717	--
Operating Expenses	29,384	5,799	12,642	--	10,943	--
Other Non Operating Income (Expenses)	49	--	148	--	-99	--
Pretax Income	8,178	2,003	2,593	--	3,582	--
Income Tax Expense	1,463	420	332	--	711	--
Net Income	9,427	1,614	2,001	--	5,812	--
Net Income Growth	--	--	-40%	--	159%	--
Shares Outstanding (Diluted)	1,204.2	1,204.2	1,219.84	--	1,231.35	--
Shares Change (YoY)	--	--	-3%	--	-2%	--
EPS (Diluted)	7.82	1.34	1.65	--	4.71	--
EPS Growth	--	--	-37%	--	165%	--
Free Cash Flow	10,662	1,683	-93	3,750	364	1,938
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	72.07%	72.09%	71.75%	--	72.44%	--
Operating Margin	21.37%	20.51%	21.93%	--	21.16%	--
Profit Margin	16.26%	14.35%	7.88%	--	27.23%	--
Free Cash Flow Margin	18.39%	14.96%	-0.36%	--	1.7%	--
EBITDA	14,700	2,842	6,564	--	5,294	--
EBITDA Margin	25.36%	25.27%	25.86%	--	24.8%	--
D&A For EBITDA	2,311	535	999	--	777	--
EBIT	12,389	2,307	5,565	--	4,517	--
EBIT Margin	21.37%	20.51%	21.93%	--	21.16%	--
Effective Tax Rate	17.88%	20.96%	12.8%	--	19.84%	--

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

57,960

11,244

25,375

21,341

Revenue Growth (YoY)

16%

Cost of Revenue

16,187

3,138

7,168

5,881

Gross Profit

41,773

8,106

18,207

15,460

Selling, General & Admin

11,870

2,327

5,037

4,506

Research & Development

9,589

1,747

4,125

3,717

Operating Expenses

29,384

5,799

12,642

10,943

Other Non Operating Income (Expenses)

148

-99

Pretax Income

8,178

2,003

2,593

3,582

Income Tax Expense

1,463

420

332

711

Net Income

9,427

1,614

2,001

5,812

Net Income Growth

-40%

159%

Shares Outstanding (Diluted)

1,204.2

1,219.84

1,231.35

Shares Change (YoY)

-3%

-2%

EPS (Diluted)

7.82

1.34

1.65

4.71

EPS Growth

-37%

165%

Free Cash Flow

10,662

1,683

-93

3,750

364

1,938

Free Cash Flow Per Share

Gross Margin

72.07%

72.09%

71.75%

72.44%

Operating Margin

21.37%

20.51%

21.93%

21.16%

Profit Margin

16.26%

14.35%

7.88%

27.23%

Free Cash Flow Margin

18.39%

14.96%

-0.36%

1.7%

EBITDA

14,700

2,842

6,564

5,294

EBITDA Margin

25.36%

25.27%

25.86%

24.8%

D&A For EBITDA

2,311

535

999

777

EBIT

12,389

2,307

5,565

4,517

EBIT Margin

21.37%

20.51%

21.93%

21.16%

Effective Tax Rate

17.88%

20.96%

12.8%

19.84%

Follow-Up Questions

What are Sanofi's key financial statements?



According to the latest financial statement (Form-10K), Sanofi has a total asset of $0, Net loss of $0

What are the key financial ratios for SNY?



Sanofi's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Sanofi's revenue broken down by segment or geography?



Sanofi largest revenue segment is Total Vaccine, at a revenue of 7,936,000,000 in the most earnings release.For geography, United States is the primary market for Sanofi, at a revenue of 22,176,000,000.

Is Sanofi profitable?



no, according to the latest financial statements, Sanofi has a net loss of $0

Does Sanofi have any liabilities?



no, Sanofi has liability of 0

How many outstanding shares for Sanofi?



Sanofi has a total outstanding shares of 0

Sanofi (SNY) Financial

SNY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Sanofi?

Sanofi (SNY) Financial

SNY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Sanofi?

SNY Income

Follow-Up Questions

What are Sanofi's key financial statements?

What are the key financial ratios for SNY?

How is Sanofi's revenue broken down by segment or geography?

Is Sanofi profitable?

Does Sanofi have any liabilities?

How many outstanding shares for Sanofi?